Cyrus: In summary, I want to express that we remain very confident and optimistic about the future for Leronlimab. We are excited to continue the development of NASH, Oncology, and other HIV related indications that we believe will lead to maximizing shareholder value. For me personally, I am thrilled to be here and to lead the company and to pursue the indications which initially attracted me to Leronlimab and then confident that our board and SAB members are aligned with our vision and are well suited to ensuring that this company properly executes and becomes successful as we embark on our new path forward.

I rest well believing Cyrus and the very talented and board and advisors would not risk there careers for a lost cause. I also think they have seen under the hood and we are on a shorter timeline than the years of trials. I smell partnership and acquisition.